Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

Analysts' mean price target for ArriVent BioPharma (AVBP) implies a 72.4% upside. The note cautions that mean price-targets are imperfect, but strong analyst agreement in raising earnings estimates signals potential upside for the stock despite elevated uncertainty.

Analysis

Analysts' mean price target for ArriVent BioPharma (AVBP) implies a 72.4% upside. The note cautions that mean price-targets are imperfect, but strong analyst agreement in raising earnings estimates signals potential upside for the stock despite elevated uncertainty.